Company Announcement

8 October 2012

Novo Nordisk A/S – Share repurchase programme

On 9 August 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 9 August 2012 to 29 October 2012.

Since the announcement as of 1 October 2012, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	**1,332,511**		**1,230,247,128**
1 October 2012	37,347	922.82	34,464,379
2 October 2012	37,758	931.43	35,169,040
3 October 2012	36,974	929.70	34,374,643
4 October 2012	37,285	936.87	34,931,179
5 October 2012	36,760	942.53	34,647,443
Accumulated under the programme	**1,518,635**		**1,403,833,812**

With the transactions stated above, Novo Nordisk owns a total of 16,560,229 treasury shares, corresponding to 3.0% of the share capital. The total amount of shares in the company is 560,000,000 including treasury shares.

Novo Nordisk A/S
Investor Relations

Novo Allé
2880 Bagsværd
Denmark

Telephone:
+45 4444 8888
Telefax:
+45 4444 6626

Internet:
novonordisk.com

CVR no:
24256790

Novo Nordisk expects to repurchase B shares worth DKK 12.0 billion during a 12 month period beginning 2 February 2012. As of 5 October 2012, Novo Nordisk has repurchased a total of 11,884,393 B shares equal to a transaction value of DKK 9,903,833,190.

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media:

Anne Margrethe Hauge
Tel: (+45) 4442 3450
amhg@novonordisk.com

Investors:

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303
krop@novonordisk.com

Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com

Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com

In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
kiau@novonordisk.com

Jannick Lindegaard
Tel: (+1) 609 786 4575
jlis@novonordisk.com

Novo Nordisk A/S
Investor Relations

Novo Allé
2880 Bagsværd
Denmark

Telephone:
+45 4444 8888
Telefax:
+45 4444 6626

Internet:
novonordisk.com

CVR no:
24256790